BEIJING, Oct. 24 (Xinhua) -- The following is a summary of published science and technology news of China.

PROBIOTICS FROM CHINESE TRADITIONAL FERMENTED FOOD

Probiotics from the Chinese traditional fermented food Jiangshui have been found capable of helping to treat hyperuricemia, a key biochemical basis of gout, according to Lanzhou University.

A research team from the School of Life Sciences under Lanzhou University found that the fermentum GR-3 strain isolated from Jiangshui can degrade uric acid, said Li Xiangkai, the team leader and a professor with the university.

As a popular traditional Chinese food, Jiangshui is normally made from fermented vegetables. A previous study by the study team showed that Jiangshui probiotics could alleviate hyperuricemia and gout in mice. The researchers then made yogurt with GR-3 strain isolated from Jiangshui, and conducted a two-month human trial on 120 volunteers with hyperuricemia.

CHINESE WIND TURBINES

The Chaiyaphum wind farm hosts 32 of China's Goldwind wind turbines with a total capacity of 80 MW and is operated by EGCO, a major energy producer affiliated to the largest state utility Electricity Generating Authority of Thailand.

Goldwind is an example of Chinese companies that have been active in Thailand's renewable energy market. The well-known Sino-Thai cooperation projects also include the hydro-floating solar hybrid project at the Sirindhorn Dam, which launched its commercial operation late last year.

In addition, Chinese carmakers like SAIC, Great Wall Motor and BYD have successively set up factories in Thailand, becoming strong competitors in the country's electric vehicle market.

COVID-19 VACCINES

At least 46 COVID-19 vaccines are being tested in human trials in China and more than 20 in overseas clinical trials as the country pushes forward its vaccine research and development through multiple tech routes.

Among them, three inactivated monovalent vaccines designed to neutralize Omicron variants are in testing for sequential immunization in the Chinese mainland, Hong Kong and the United Arab Emirates, and these tests are going well.

In addition, two domestically-developed mRNA-based COVID-19 vaccine candidates have proven effective in preclinical trials, showing their potential for human tests, according to a June paper published in the journal Emerging Microbes & Infections.